| crwefinancelogo2signup3m | | | | under its contracts with the U.S. government. |
| A5 Laboratories Inc. (OTC.BB:AFLB) has recently | | | | |
| reported that the company has submitted a | | | | |
| provisional patent application to protect its technology | | | | |
| for its products. The patent application generally | | | | |
| describes the company's new method for producing | | | | |
| therapeutic proteins as well as providing details of the | | | | Signup for FREE Daily Stock Alerts From |
| production of company's lead product VI-1718. A5 | | | | CRWEFinance.com/signup |
| Lab's lead product VI-1718 has potential broad based | | | | THIS IS NOT A RECOMMENDATION TO BUY OR |
| applications for the treatment of certain types of | | | | SELL ANY SECURITY! |
| cancer as well as multiple sclerosis and viral infections. | | | | Disclaimer: Never invest in any stock featured on our |
| President and CEO of A5 Dr. Richard Azani stated | | | | site or emails unless you can afford to lose your |
| The submission of this patent application is a very | | | | entire investment. publisher and its affiliates and |
| significant milestone in the development of our | | | | contractors are not registered investment advisers or |
| interferon-based products. I am very proud of our | | | | broker/dealers. Our disclaimer is to be read and fully |
| research team for their tireless work in completing | | | | understood before using our site, reading our |
| the scientific and technological basis for this patent. | | | | newsletter or joining our email list. Release of Liability: |
| We are now ready to advance the company's plans | | | | Through use of this website viewing or using, you |
| towards production and commercialization of these | | | | agree to hold report and Crown Equity Holdings, Inc. |
| products. | | | | CRWE, its operators, shareholders, employees and/or |
| AFLB is a contract research based organization | | | | contractors harmless and to completely release them |
| servicing the pharmaceutical and biotechnology | | | | from any and all liability due to any and all loss |
| companies in North America. The company utilizes its | | | | (monetary or otherwise), damages (monetary or |
| research capabilities to license and acquire novel | | | | otherwise) that you may occur. (read more )Rule 17B |
| biotechnology products for development and | | | | requires disclosure of payment for investor relations. |
| commercialization. | | | | Crown Equity Holdings, Inc. (CRWE.OB) is a newswire |
| | | | | as well as an IR and PR firm. Crown Equity Holdings, |
| | | | | Inc. (CRWE.OB), in some cases, provides media |
| | | | | advertising and public awareness for both public and |
| XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery | | | | private companies, as well as disseminating news. As |
| and development of therapeutic antibodies, recently | | | | such, in some cases, when Crown Equity Holdings, |
| reported that the Committee for Orphan Medical | | | | Inc. (CRWE.OB) advertises for a particular client, |
| Products of the European Medicines Agency (EMA) | | | | Crown Equity Holdings, Inc. (CRWE.OB) charges an |
| has adopted a positive opinion and recommends the | | | | advertising fee which it must disclose under SEC Rule |
| granting of orphan medicinal product designation for | | | | 17B. The fee may be in cash, in free trading stock, in |
| XOMA 052, an antibody to interleukin-1 beta, for the | | | | restricted stock or in any combination thereof. Crown |
| treatment of Behcet's disease. Positive opinions are | | | | Equity Holdings, Inc. (CRWE.OB), if paid in stock, can |
| submitted to the European Commission for decision | | | | and may sell those securities during the advertising |
| and are generally adopted within 30 days of receipt. | | | | period. Crown Equity Holdings, Inc. (CRWE.OB) has |
| XOMA develops and manufactures novel antibody | | | | received eight thousand dollars in cash from a third |
| therapeutics for its own proprietary pipeline as well as | | | | party (Winning Media) for (one) day of advertising |
| through license and collaborative agreements with | | | | for A5 Laboratories Inc. (AFLB. |
| pharmaceutical and biotechnology companies, and | | | | |